Please use this identifier to cite or link to this item:
Title: Clinical evaluation of allogeneic eye drops from cord blood platelet lysate
Author: Samarkanova, Dinara
Martín, Sara
Bisbe, Laia
Puig, Javier
Calatayud Pinuaga, Marta
Rodriguez Gómez, Luciano
Azqueta, Carmen
Coll, Ruth
Casaroli Marano, Ricardo Pedro
Madrigal, Alejandro
Rebulla, Paolo
Querol Giner, Sergi
Barcelona CBED Study Group.
Keywords: Malalties de la còrnia
Cornea diseases
Issue Date: 31-Jul-2020
Publisher: Edizioni SIMTI
Abstract: Background - Current treatments for several corneal lesions show limited efficacy. Here we report the clinical evaluation of the efficacy of a novel eye drop preparation produced in a public cord blood (CB) bank. Material and methods - In a multicentre, retrospective, consecutive case study we evaluated 33 patients (46 eyes) unresponsive to conventional treatments who required urgent intervention. The patients were given allogeneic eye drops obtained from cord blood platelet lysate (CBED) to treat severe ocular surface lesions under a compassionate use protocol. The CBED were prepared from CB units donated for haematopoietic stem cell transplantation that did not contain the minimum stem cell dose required for this use. Patients were grouped by acute conditions (neurotrophic ulcers: group I; other corneal ulcers: group II; corneal burns: group III), and chronic conditions (ocular graft-versus-host disease: group IV; severe dry eye syndrome: group V). The patients received one or two drops of the product to the affected eye four to six times per day for 19 days. A further 19-day cycle of treatment could be repeated according to the initial clinical response. Results - Patients received a median of 19 CBED vials (interquartile range 19-57, range 19-442) to complete the therapy. Group I-II-III patients showed full and partial ulcer recovery in 25 (78%) and six (19%) eyes respectively. One eye (3%) did not respond to treatment. For groups IV-V improvement was reported for 12 (85%) eyes and lesions worsened on treatment in both eyes (15%) of one patient. No severe adverse events were directly attributed to CBED. Discussion - Promptly available CBED resulted in a well-tolerated allogeneic treatment that showed evidence of efficacy in this cohort of patients. These positive results support further studies on CBED from platelet lysate as a novel product of CB banks. A prospective clinical trial in neurotrophic keratitis (NCT03084861) is ongoing to confirm these preliminary data. Keywords: cord blood, eye drops, corneal ulcers, neurotrophic keratitis, dry eye.
Note: Reproducció del document publicat a:
It is part of: Blood Transfusion, 2020, vol. 19, num. 4, p. 347-356
Related resource:
ISSN: 1723-2007
Appears in Collections:Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Files in This Item:
File Description SizeFormat 
710221.pdf1.62 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.